Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Hotter is not more aggressive: baseline SUVmax in FL

N. George Mikhaeel

Blood (2020) 135 (15): 1191–1192.

https://doi.org/10.1182/blood.2020004986

Published: 2020

Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman

Blood (2020) 135 (15): 1214–1218.

https://doi.org/10.1182/blood.2019001091

Published: 2020

Includes: Supplemental data

Journal Articles

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Carla Casulo, Michael Herold, MD, Wolfgang Hiddemann, MD PhD, Sunil Iyengar, MD, Robert E. Marcus, FRCP, John F. Seymour, MBBS, PhD FRACP, Aino Launonen, MSc, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Farheen Mir, MBBS, MD

Blood (2019) 134 (Supplement_1): 5268.

https://doi.org/10.1182/blood-2019-123466

Published: 2019

Journal Articles

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Miguel A Canales, MD PhD, Thomas A Buchholz, MD, James R Mason, MD, Joana M Parreira, MD, Monique S Tomiczek, MSc, Kai Hübel, MD

Blood (2019) 134 (Supplement_1): 5269.

https://doi.org/10.1182/blood-2019-123638

Published: 2019

Journal Articles

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Tu My To, PhD, Keith L. Dawson, DNP, MS, Anthony S Masaquel, PhD MPH, Arpamas Seetasith, PhD

Blood (2019) 134 (Supplement_1): 4721.

https://doi.org/10.1182/blood-2019-123408

Published: 2019

Journal Articles

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Skander Jemaa, MS, Jill Fredrickson, PhD, Alexandre Coimbra, PhD, Richard AD Carano, PhD, Tarec Christoffer C. El-Galaly, MD, Andrea Knapp, PhD, Tina G Nielsen, MD PhD, Deniz Sahin, BSc, Thomas Bengtsson, PhD, Alex de Crespigny, PhD

Blood (2019) 134 (Supplement_1): 4666.

https://doi.org/10.1182/blood-2019-124793

Published: 2019

Journal Articles

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Faouzi Djebbari, Furqaan Kaji, Louise Stanton, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 5884.

https://doi.org/10.1182/blood-2019-122213

Published: 2019

Journal Articles

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Vindi Jurinovic, PhD, Verena Passerini, PhD, Mikkel Z Oestergaard, PhD, Andrea Knapp, PhD, Kirsten Mundt, PhD, Shamzah Araf, MRCP, MBBS, PhD, Julia Richter, PhD, Jude Fitzgibbon, PhD, Wolfram Klapper, Robert E. Marcus, FRCP, Andrew Davies, MD PhD, Michael Herold, MD, Wolfgang Hiddemann, PhD, Michael Unterhalt, PhD, Eva Hoster, PhD, Oliver Weigert, MD

Blood (2019) 134 (Supplement_1): 122.

https://doi.org/10.1182/blood-2019-130208

Published: 2019

Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai

Blood (2019) 133 (2): 137–146.

https://doi.org/10.1182/blood-2018-04-848044

Published: 2019

Includes: Supplemental data

Journal Articles

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Allison M. Winter, MD, Loretta J. Nastoupil, MD, Melody R. Becnel, MD, James R. Cerhan, MD PhD, Thomas M. Habermann, MD, Brian K. Link, MD, Matthew J. Maurer, MS, Bita Fakhri, MD MPH, Prathima Reddy, MD, Stephen D. Smith, MD, Dhruvika Mukhija, MD, Deepa Jagadeesh, MD MPH, Amrita Desai, MD, Juan Pablo Alderuccio, MD, Izidore S. Lossos, MD, Pooja Mehra, MD, Craig A. Portell, MD, Christopher R. D'Angelo, MD, Vaishalee P. Kenkre, MD, Max L. Goldman, MD, Oscar Calzada, BS, Jonathon B. Cohen, MD MS, Mohammad Junaid Hussain, MD, Nilanjan Ghosh, MD PhD, Yang Liu, MD, Stefan Klaus Barta, MD MRCP, MS, Paolo F Caimi, MD, Adam Kittai, MD, Alexey V Danilov, MD PhD, Timothy Tiutan, MD, Peter Martin, FRCPC, MD MS, Nathalie Danielson, MSN, RN, ACNP-BC, Manali Kamdar, MD, Abhigna Kodali, MD, Andrew M. Evens, DO, MSc, Brad S Kahl, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 4146.

https://doi.org/10.1182/blood-2018-99-118530

Published: 2018

Journal Articles

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Farheen Mir, MBBS, Sally F Barrington, Michel Meignan, Helen Brown, Tina Nielsen, Deniz Sahin, Judith Trotman

Blood (2018) 132 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2018-99-116686

Published: 2018

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD

Blood (2018) 132 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2018-99-114620

Published: 2018

Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 396.

https://doi.org/10.1182/blood-2018-99-115930

Published: 2018

Journal Articles

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Blood (2018) 132 (Supplement 1): 4109.

https://doi.org/10.1182/blood-2018-99-116750

Published: 2018

Journal Articles

Identification of Patients with Follicular Lymphoma Patients at Risk of Failing Frontline Immunochemotherapy and Rituximab Maintenance

Marta Garcia Recio, Sandra Pérez-León, Leyre Bento, MD, Antonio Salar, MD PhD, Blanca Sanchez-Gonzalez, Jordi Gines, Beatriz Robredo, Lucia García, Sara Aida Jiménez-Julià, Jordi Martínez-Serra, PhD, Antonia Sampol, MD PhD, Antonio Gutiérrez, MD PhD

Blood (2018) 132 (Supplement 1): 5339.

https://doi.org/10.1182/blood-2018-99-119551

Published: 2018

Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Sally F Barrington, Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Wolfgang Hiddemann, Robert Marcus, Tina Nielsen, Federico Mattiello, Harald Zeuner, Michel Meignan

Blood (2018) 132 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2018-99-117235

Published: 2018

Journal Articles

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Sarah Hartley, MBBS, MRCP, Amy Beech, Catherine Griffiths, Faith Richardson, Helen Knight, Andrew K. McMillan, FRCP, Mark Bishton, Chris P Fox

Blood (2017) 130 (Supplement 1): 3586.

https://doi.org/10.1182/blood.V130.Suppl_1.3586.3586

Published: 2017

Journal Articles

Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Candice Jamois, Ekaterina Gibiansky, Leonid Gibiansky, Vincent Buchheit, Pauline Baumlin, Denis Sahin, Guillaume Cartron, Robert Marcus, Wolfgang Hiddemann, MD PhD, John F Seymour, MBBS, PhD, Jonathan C Strefford, PhD, Georgina Meneses-Lorente, Nicolas Frey, Günter Fingerle-Rowson

Blood (2017) 130 (Supplement 1): 3848.

https://doi.org/10.1182/blood.V130.Suppl_1.3848.3848

Published: 2017

Journal Articles

Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model

Kubra Kamisoglu, Alex Phipps, Candice Jamois, Vincent Buchheit, Georgina Meneses-Lorente, Günter Fingerle-Rowson, Jonathan Wagg, Donald E Mager

Blood (2017) 130 (Supplement 1): 1267.

https://doi.org/10.1182/blood.V130.Suppl_1.1267.1267

Published: 2017

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Hotter is not more aggressive: baseline SUVmax in FL

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients with Previously Untreated Advanced Follicular Lymphoma

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Follicular Lymphoma Frontline Immuno-Chemotherapy: Survival Outcomes and Infection-Related Morbidity

Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials

Identification of Patients with Follicular Lymphoma Patients at Risk of Failing Frontline Immunochemotherapy and Rituximab Maintenance

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Influence of Baseline Disease Characteristics and Exposure to Obinutuzumab on Clinical Outcome in Patients with Previously Untreated Advanced Follicular Lymphoma Treated with Obinutuzumab-Based Immunochemotherapy in the GALLIUM Trial

Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only